Adaptive Biotechnologies annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies Free Cash Flow (FCF) History (ADPT)
Adaptive Biotechnologies reported −$48.9M in free cash flow for fiscal 2025, an increase of $49.9M from the previous fiscal year, with a free cash flow margin of −17.67%.
View full Adaptive Biotechnologies company overviewAdaptive Biotechnologies free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$48.9M | $49.9M | — | −17.67% |
| 2024 | 2024-12-31 | −$98.9M | $68.1M | — | −55.25% |
| 2023 | 2023-12-31 | −$167.0M | $33.3M | — | −98.09% |
| 2022 | 2022-12-31 | −$200.3M | $54.2M | — | −108.09% |
| 2021 | 2021-12-31 | −$254.5M | −$86.0M | — | −164.87% |
| 2020 | 2020-12-31 | −$168.5M | −$362.7M | — | −171.26% |
| 2019 | 2019-12-31 | $194.2M | $232.8M | — | +228.28% |
| 2018 | 2018-12-31 | −$38.6M | −$1.3M | — | −69.27% |
| 2017 | 2017-12-31 | −$37.3M | — | — | −96.96% |
Adaptive Biotechnologies quarterly free cash flow
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.6M | $5.5M | — | −10.60% |
| Q1 2026 | 2026-03-31 | −$10.3M | $19.4M | — | −14.58% |
| Q4 2025 | 2025-12-31 | $1.4M | $14.0M | — | +1.98% |
| Q3 2025 | 2025-09-30 | −$7.5M | $19.9M | — | −8.02% |
| Q2 2025 | 2025-06-30 | −$13.1M | $5.9M | — | −22.22% |
| Q1 2025 | 2025-03-31 | −$29.7M | $10.1M | — | −56.71% |
| Q4 2024 | 2024-12-31 | −$12.6M | $15.7M | — | −26.49% |
| Q3 2024 | 2024-09-30 | −$27.4M | $22.1M | — | −59.03% |
| Q2 2024 | 2024-06-30 | −$19.0M | $8.2M | — | −44.07% |
| Q1 2024 | 2024-03-31 | −$39.9M | $22.2M | — | −95.20% |
| Q4 2023 | 2023-12-31 | −$28.2M | $4.3M | — | −61.66% |
| Q3 2023 | 2023-09-30 | −$49.5M | −$1.6M | — | −130.44% |
| Q2 2023 | 2023-06-30 | −$27.3M | $25.1M | — | −55.70% |
| Q1 2023 | 2023-03-31 | −$62.1M | $5.5M | — | −164.89% |
| Q4 2022 | 2022-12-31 | −$32.6M | $30.5M | — | −58.99% |
| Q3 2022 | 2022-09-30 | −$47.8M | $10.2M | — | −100.02% |
| Q2 2022 | 2022-06-30 | −$52.4M | $6.9M | — | −119.93% |
| Q1 2022 | 2022-03-31 | −$67.5M | $6.6M | — | −174.86% |
| Q4 2021 | 2021-12-31 | −$63.1M | −$13.9M | — | −166.28% |
| Q3 2021 | 2021-09-30 | −$58.1M | −$6.7M | — | −147.12% |
| Q2 2021 | 2021-06-30 | −$59.3M | −$25.9M | — | −153.89% |
| Q1 2021 | 2021-03-31 | −$74.1M | −$39.5M | — | −192.72% |
| Q4 2020 | 2020-12-31 | −$49.2M | −$20.0M | — | −163.04% |
| Q3 2020 | 2020-09-30 | −$51.4M | −$17.8M | — | −195.30% |
| Q2 2020 | 2020-06-30 | −$33.3M | −$15.8M | — | −158.85% |
| Q1 2020 | 2020-03-31 | −$34.6M | −$309.0M | — | −165.32% |
| Q4 2019 | 2019-12-31 | −$29.2M | — | — | −120.65% |
| Q3 2019 | 2019-09-30 | −$33.6M | −$19.7M | — | −128.82% |
| Q2 2019 | 2019-06-30 | −$17.5M | — | — | −79.02% |
| Q1 2019 | 2019-03-31 | $274.5M | — | — | +2167.00% |
| Q3 2018 | 2018-09-30 | −$13.9M | — | — | −80.73% |
Adaptive Biotechnologies free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$168.5M to −$48.9M, a net increase of $119.5M. Adaptive Biotechnologies's latest reported quarter, Q2 2026, generated −$7.6M in free cash flow, an increase of $5.5M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Adaptive Biotechnologies source filings ↗Community posts
Adaptive reports broader NCCN guidance for residual-disease testing
Adaptive ($ADPT) Biotechnologies said updated National Comprehensive Cancer Network guidance for multiple myeloma gives measurable residual disease testing a dedicated section and names clonoSEQ as a testing option. The update specifies a p ...
